Abstract
Soft tissue sarcomas (STS) are a rare and heterogeneous group of mesenchymal tumors accounting for approximately 1% of adult solid malignancies (1). Chemotherapy remains the mainstay of treatment for patient with metastatic STS. Molecular-targeted therapies are active in selected and very rare histological subtypes such as crizotinib in ALK-rearranged inflammatory myofibroblastic tumor (2). To our knowledge, PD(L)1 inhibitors seem not to have significant activity in STS, but it is too early to conclude (3). Up to now second line treatment options (dacarbazine, ifosfamide, gemcitabine-docetaxel, trabectedin and pazopanib) were based on the results of phase II/III studies in which overall survival (OS) is not the primary endpoint or without significant improvement in OS (4-7). Recently, Patrick Schoffski and colleagues reported in a randomised multicentre phase III trial that treating advanced liposarcoma (LPS) and leiomyosarcoma (LMS) with eribulin an improvement in OS compared with dacarbazine (8).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
